Spanish CDMO invests €200k to protect clients' products
Idifarma's EU-GMP approved plant in Pamplona, Spain.
Investment will enable Idifarma to both serialise commercial batches manufactured by them for clients and offer standalone serialisation services.
Spanish CDMO Idifarma has announced its plans to meet forthcoming EU serialisation regulations with a €200k investment.
The investment will see the installation of the Antares Vision Print&Check EVO-TE carton serialisation station at its EU-GMP approved plant in Pamplona, Spain and comes ahead of the EU Falsified Medicines Directive’s (EU FMD) February 2019 deadline for the serialisation of licensed drug products.
Luis Oquiñena, general manager and co-founder of Idifarma said: “Recognising our role in combatting counterfeit medicines and supporting our customers with new regulatory requirements, we’ve taken a proactive approach and have been preparing for the arrival of this legislation for a long time now.
“We have worked closely with the manufacturers of this machine, and track and trace software vendors to specify our requirements according to our clients’ needs across the world.
“This machine offers us the flexibility to upgrade for future regulatory or client requirements and will enable us to help protect our clients’ products and the public against counterfeit pharmaceuticals.”
The company anticipates that the equipment will be operational six months ahead of the EU FMD deadline.
Oquiñena added: “Our investment will offer real support to our clients as they too prepare to meet the regulations. We will be able to serialise commercial batches manufactured by Idifarma for clients, but we will also be able to offer standalone serialisation services as an outsourcing partner.
“As the deadline draws closer we fully expect to see demand for these specialised outsourced services to increase.”
The investment in serialisation follows the expansion of its capsule filling capabilities in 2017 and strengthens Idifarma’s position as a specialised contract partner for the development and manufacturing of oral solid dosage forms, including high potency compounds and niche pharmaceuticals requiring small batches.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.